Colon cancer continues to impose a solid all-encompassing health burden regardless of important advances in screening, surgical methods, and intrinsic therapies. Current situation policies are frequently restricted for one development of drug opposition, situation-related toxicity, and extreme monetary costs, underscoring the need for alternative and complementary healing approaches. Drug repurposing, that involves labeling new dispassionate applications for settled cures, has gained growing consideration as a practical and economic planning in oncology. In this framework, certain established anthelmintic (antagonistic-worm) drugs, specifically benzimidazole descendants such as mebendazole, have arose as hopeful anticancer candidates. Accumulating preclinical evidence shows that mebendazole applies strong antiproliferative belongings against colon tumor cells in a shot- and period-dependent approach, while broadly sparing common containers. Mechanistic studies indicate that allure anticancer endeavor is primarily interceded through turmoil of microtubule dynamics, happening in G2/M container-cycle arrest and mitotic calamity. This is followed by incitement of intrinsic apoptotic pathways, containing mitochondrial sheath depolarization, caspase activation, and timbre of supporting- and anti-apoptotic proteins. Additional belongings contain inhibition of angiogenesis, meddling accompanying tumor level of glucose in blood absorption, and suppression of oncogenic indicating pathways that are fault-finding for tumor progress and continuation. Evidence from animal models further supports these findings, accompanying meaningful tumor development restriction observed in colon malignancy xenograft studies and littlest systemic toxicity. Given allure spoken bioavailability, low cost, and long past of dependable clinical use, mebendazole shows a irresistible nominee for repurposing in colorectal cancer healing. Overall, the convenient data support further hearing concerning this common anthelmintic drug in well-planned dispassionate trials, either as a monotherapy or together accompanying existing standard situations.

Colorectal cancer is still one of the top causes of cancer illness and death around the world. Sure, surgery [1] chemo, and targeted treatments have come a long way, but patients still run into brick walls—treatment resistance, nasty side effects, and limits in what doctors can do.[2] That’s why there’s so much interest these days in finding new treatments that actually work and don’t break the bank. Drug repurposing is a hot topic here. Basically, it means taking drugs we already use for one thing and seeing if they can help with something else. It’s a smart move: we already know they’re safe, it’s faster to get them to patients, and it costs less [3]. Lately, some old anti-parasitic and anti-worm drugs have popped up as surprising contenders in cancer research [4]. Those benzimidazole-based meds people usually take for intestinal worms? They’re turning up with anticancer effects—not just for colon cancer, but also for brain, breast, and lung cancers. [5,6] What’s going on? Well, these drugs latch onto β-tubulin in parasites and mess with their microtubules. Turns out, they do pretty much the same thing in cancer cells—wrecking the cell’s structure, stalling division, and pushing them toward cell death. In this article, I’m digging into the evidence behind one of these common anti-worm drugs and its punch against colon cancer cells.

Literature Review

Let’s rewind a bit. Early lab studies spotted that benzimidazole anthelmintics slow down cancer cell growth by messing with microtubules. Later research showed these drugs put the brakes on colon cancer cell lines like HCT-116, HT-29, and SW480. But that’s not the whole story. There’s a lot more going on at the molecular level. These drugs fire up caspase-3 and caspase-9, mess with mitochondria, and tip the balance toward cell death by increasing the Bax/Bcl-2 ratio. On top of that, they cut off the tumor’s blood supply and starve the cells of glucose, basically putting the cancer on a strict diet. Animal studies back this up. Give mice the drug by mouth, and you see tumors shrink—sometimes dramatically. The best part? The mice don’t show major side effects. All of these points to common anti-worm drugs being more than just parasite killers—they’re showing real promise as cancer fighters.

Research Methodology

For this review, I mixed narrative and systematic approaches. I pulled peer-reviewed studies from big biomedical databases, sticking to English-language papers. I focused on research that looked at colon cancer cells in the lab or tested tumor growth in animals. If a paper was just a review, editorial, or about something other than cancer, I left it out. I zeroed in on details like drug dose, how long cells or animals were exposed, what happened to cell survival, which markers of cell death popped up, and how tumors responded. Then I pulled everything together, looking for patterns that made sense biologically.

When the numbers were there, I summed up the data with averages and percentage changes compared to control groups. Most studies used standard tests—like Student’s t-test or one-way ANOVA—and called p-values under 0.05 significant. Since the experiments weren’t all set up the same way, I didn’t try to run a full-blown meta-analysis.

In labs, treating colon cancer cells with the anti-worm drug cut their numbers by 40–80%, depending on the dose and how long the treatment lasted. Flow cytometry kept turning up the same thing: cancer cells getting stuck in the G2/M phase (basically, they can’t divide) and more of them dying. In animals, the drug slowed tumor growth by about 50–70% compared to untreated controls. The mice didn’t lose much weight, and their bloodwork looked alright—so the drug seems to hit tumors hard without hammering the rest of the body. All in all, the evidence stacks up: this common anti-worm drug packs a serious anticancer punch and looks pretty safe, at least so far.

Table 1: Summary of Anthelmintic Drug Effects on Colon Cancer Models.

Figure 1: Mechanistic Pathways of Anthelmintic Drug–Mediated Colon Cancer Cell Death.

Source: Figure 1 is compiled and adapted from published experimental studies investigating the anticancer mechanisms of anthelmintic drugs in colorectal cancer models.

Figure 2: Translational Drug-Repurposing Framework.

Source: Figure 2 is adapted from established drug-repurposing and translational oncology frameworks applied to antiparasitic agents.

The anticancer effects against colon cancer cells by common anti-helmintic drugs are suggested to occur by more than one mechanism, which converge on a single endpoint. Microtubule destabilizing agents interfere with cell mitosis, whereas mitochondrial dysfunction induces apoptosis. On the part of the medical fraternity, the oral bioavailability and cost-effectiveness, and proven safety record for these drugs make them potential candidates for repositioning. However, certain hurdles still exist in the area of optimizing the dosages and bioavailability of the drugs and finding susceptible patient populations.

Growing preclinical data available now suggest that a popular anti-worm drug possesses potent inhibitory properties against colon cancer cells. Its multi-targeting properties, along with good-to-excellent safety, make it an ideal candidate for translation and clinical development. Use of these drugs could perhaps serve as an economic additional approach in managing colorectal cancer.

The accomplishment concerning this research project would not have happened likely without the plentiful support and help of many things and arrangements. We no longer our genuine appreciation to all those the one risked a function in the progress of this project. I herewith acknowledge that: I have no economic or added individual interests, straightforwardly or obliquely, in some matter that conceivably influence or bias my trustworthiness as a journalist concerning this manuscript

Conflicts of Interest:

The authors declare that they have no conflicts of interest.

Financial Support and Protection:

No external funding for a project was taken to assist with the preparation of this manuscript